摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-fluoroloxoprofen | 1241405-00-4

中文名称
——
中文别名
——
英文名称
2-fluoroloxoprofen
英文别名
2-(2-fluoro-4-[(2-oxocyclopentyl)methyl]phenyl)propanoic acid;2-[2-fluoro-4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid
2-fluoroloxoprofen化学式
CAS
1241405-00-4
化学式
C15H17FO3
mdl
——
分子量
264.297
InChiKey
YDEVCGCLYOHOIL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    19
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    54.4
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-fluoroloxoprofen 在 sodium hydroxide 作用下, 以 乙醇 为溶剂, 反应 2.0h, 以94.7%的产率得到fluoroloxoprofen sodium salt
    参考文献:
    名称:
    Properties and Synthesis of 2-{2-Fluoro (or Bromo)-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic Acid: Nonsteroidal Anti-inflammatory Drugs with Low Membrane Permeabilizing and Gastric Lesion-Producing Activities
    摘要:
    We previously proposed that membrane permeabilization activity of NSAIDs is involved in NSAID-induced gastric lesions. We here synthesized derivatives of loxoprofen that have lower membrane permeabilization activity than other NSAIDs. Compared to loxoprofen, the derivatives 10a and 10b have lower membrane permeabilization activity and their oral administration produced fewer gastric lesions but showed an equivalent anti-inflammatory effect. These results suggest that 10a and 10b are likely to be therapeutically beneficial as safer NSAIDs.
    DOI:
    10.1021/jm101116s
  • 作为产物:
    参考文献:
    名称:
    LOXOPROFEN DERIVATIVE AND PHARMACEUTICAL PREPARATION CONTAINING THE SAME
    摘要:
    提供了一种新型洛索洛芬衍生物,该衍生物没有胃肠道障碍等副作用,同时具有优秀的抗炎和镇痛作用,其化学结构如下所示(式中R1和R2分别代表卤素原子或取代或未取代的苯基),或其药学上可接受的盐。在该衍生物中,卤素原子可选自氯原子、溴原子、氟原子和碘原子,取代苯基的取代基为卤素原子、羟基、取代或未取代的较低烷基基团、较低烷基硫基团、较低烷氧基团、硝基基团、氨基或羧基。
    公开号:
    US20120016158A1
点击查看最新优质反应信息

文献信息

  • 2-FLUOROPHENYL PROPIONIC ACID DERIVATIVES
    申请人:LTT BIO-PHARMA CO., LTD.
    公开号:US20140330026A1
    公开(公告)日:2014-11-06
    Provided are novel 2-fluorophenyl propionic acid derivatives which have excellent anti-inflammatory/analgesic effects while avoiding side effects such as gastrointestinal disorders, namely 2-fluorophenyl propionic acid derivatives represented by the formula (I) below or pharmaceutically acceptable salts thereof, [wherein, R 1 represents a hydrogen atom, a halogen atom, or a substituted or unsubstituted phenyl group, X represents —CH 2 —, —NH—, —O—, or —S—, and Y specifically represents group (II) (wherein, Z 1 represents —CO—, —CH(OH)—, or —CH 2 —, and n represents an integer of 1 or 2.)]
    提供了具有出色抗炎/镇痛效果且避免胃肠道疾病等副作用的新型2-氟苯丙酸衍生物,即由下面的式(I)所代表的2-氟苯丙酸衍生物或其药学上可接受的盐,其中,R1代表氢原子、卤原子或取代或未取代的苯基,X代表—CH2—、—NH—、—O—或—S—,Y具体表示群(II)(其中,Z1代表—CO—、—CH(OH)—或—CH2—,n代表1或2的整数)。
  • 一种洛索洛芬衍生物
    申请人:北京蓝丹医药科技有限公司
    公开号:CN109134262A
    公开(公告)日:2019-01-04
    本发明提供一种胃肠道副作用低并提高生物利用度的洛索洛芬衍生物。
  • US8431614B2
    申请人:——
    公开号:US8431614B2
    公开(公告)日:2013-04-30
  • US9221786B2
    申请人:——
    公开号:US9221786B2
    公开(公告)日:2015-12-29
  • Properties and Synthesis of 2-{2-Fluoro (or Bromo)-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic Acid: Nonsteroidal Anti-inflammatory Drugs with Low Membrane Permeabilizing and Gastric Lesion-Producing Activities
    作者:Naoki Yamakawa、Shintaro Suemasu、Masaaki Matoyama、Ayumi Kimoto、Miho Takeda、Ken-ichiro Tanaka、Tomoaki Ishihara、Takashi Katsu、Yoshinari Okamoto、Masami Otsuka、Tohru Mizushima
    DOI:10.1021/jm101116s
    日期:2010.11.11
    We previously proposed that membrane permeabilization activity of NSAIDs is involved in NSAID-induced gastric lesions. We here synthesized derivatives of loxoprofen that have lower membrane permeabilization activity than other NSAIDs. Compared to loxoprofen, the derivatives 10a and 10b have lower membrane permeabilization activity and their oral administration produced fewer gastric lesions but showed an equivalent anti-inflammatory effect. These results suggest that 10a and 10b are likely to be therapeutically beneficial as safer NSAIDs.
查看更多